Adaptilens is an innovative biotechnology company based in Boston, Massachusetts, specializing in the development of accommodating intraocular lenses (IOLs). Founded by Liane Clamen, Adaptilens aims to transform cataract surgery by providing biomimetic lens solutions that mimic the human eye's natural focusing ability. As of 2024, the company has successfully raised a total of $19.1 million, including a recent $17.5 million Series A financing round, which has been pivotal in advancing its research and development efforts.
| Attribute | Information |
|---|---|
| Founding Date | Not explicitly stated |
| Headquarters | Boston, Massachusetts, United States |
| Founder | Liane Clamen |
| Revenue | Not publicly disclosed |
| Profits | Pre-clinical stage, profits not applicable |
| Key Investors | Perceptive Xontogeny Venture Funds, Pillar VC |
| Industry | Biotechnology/Healthcare |
| Number of Employees | Approximately 218 (LinkedIn data) |
Adaptilens was founded with the goal of addressing the limitations of traditional cataract surgery, specifically the dependency on external vision aids post-surgery. Liane Clamen, who is an experienced ophthalmologist with a history of contributing to vision-correcting technology, spearheaded the initiative. The company began with seed funding of $1.6 million, supporting the early development of accommodating intraocular lenses designed to allow natural vision adjustment akin to the natural human lens.
Adaptilens' business model focuses on the development and commercialization of intraocular lenses that can restore the eye’s ability to focus naturally at various distances. Their accommodating intraocular lens (A-IOL) technology leverages novel biomimetic materials to closely replicate the functioning of a youthful, healthy eye.
Adaptilens is in the pre-clinical stage, testing its A-IOL technology to potentially revolutionize cataract surgery standards. By focusing on biomimetic lens approaches, the company aims to tap into the rapidly growing market for ophthalmic solutions. It distinguishes itself through cutting-edge materials science and a commitment to fostering a future where cataract patients can regain near-natural vision without corrective eyewear.
Adaptilens represents a promising venture in the field of ophthalmology with its accommodating intraocular lens technology under development. With significant financial backing and a visionary leadership team, it stands poised to potentially transform cataract surgical procedures and improve outcomes for millions of patients worldwide. Future expansions and successful trials may cement its status as a leader in the biotechnology and visual healthcare industries.